OIS@AAO 2014 Videos
Thomas W. Chalberg, PhD presented an update on Avalanche Biotechnologies Inc.’s pipeline of products emerging from its integrated gene therapy discovery, development, and manufacturing platform,…
Read More[creativ_media type=”vimeo” url=”https://vimeo.com/110730931″] Vicken Karageozian, MD, Co-Founder and CTO of Allegro Opthalmics LLC, updated the OIS audience on the clinical trial progress of Luminate, a…
Read MoreCEO David R. Guyer, MD reports that Phase III clinical trials of Ophthotech Corp.’s Fovista, a first-in-class anti-PDGF agent for wet AMD combination therapy, are…
Read MoreMonoclonal antibody company Xoma Corp. shared its new strategy of developing an internal pipeline of potential therapeutics. The company’s lead molecule is gevokizumab, a monoclonal…
Read MoreNovaliq GmbH is using semifluorinated alkanes to improve solubility of topical agents like cyclosporin and latanoprost on the ocular surface, according to CEO Bernhard Günther.…
Read MoreEd Timm, President and CEO of Mobius Therapeutics LLC, provided an update on the investigations into extending the company’s Mitosol platform, presently used to administer…
Read MoreGrayBug LLC is conducting preclinical work on its microparticle anti-VEGF compound GB-102, an extended-release injectable for wet AMD. The platform encapsulates the active drug ingredient…
Read MoreAmarpreet Sawhney, PhD, President and CEO of Ocular Therapeutix shared his company’s vision: to transform the treatment of eye diseases with sustained release therapeutics. Ocular’s…
Read MoreAly1337 is a novel, small-molecule multi-kinase inhibitor that Allysta Pharmaceuticals Inc. is developing to treat glaucoma, said Henry Hsu, MD, Founder and CEO. Kinase, particularly…
Read MorePublicly traded Aerie Pharmaceuticals Inc. has two Rho kinase inhibitors, or ROCK inhibitors, in development, CEO Vicente Anido, Jr, PhD, reported Rhopressa which is in phase…
Read MoreONL Therapeutics Inc. is developing Met12, a small peptide inhibitor that uses a novel mechanism to attack Fas receptor apoptosis, which has a key role…
Read MoreKala Pharmaceutical Inc. is moving its proprietary Lotoprednol Etaobnate Mucus Penetrating Particle (LE-MPP) platform through a host of trials, Interim President and CBO Charlie McDermott…
Read More
SUBSCRIBE TO OIS NEWS
Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.
We respect your privacy and promise to never send you spam.
![OIS-ANTERIOR-NEW-DATE-750x420[4300]](https://ois.net/wp-content/uploads/2020/03/OIS-ANTERIOR-NEW-DATE-750x4204300.jpg "OIS-ANTERIOR-NEW-DATE-750x420[4300]")